Claims for Patent: 8,617,823

Summary for Patent: 8,617,823

Title:	Immunomodulating compositions and methods of use thereof
Abstract:	The invention is directed to .beta.1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The .beta.1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The .beta.1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated .beta.1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.
Inventor(s):	Rubin-Bejerano; Ifat (Belmont, MA), Fink; Gerald R. (Chesnut Hill, MA)
Assignee:	Immunexcite, Inc. (Watertown, MA)
Application Number:	12/990,066
Patent Claims:	1. A method comprising steps of: assessing relative immunoglobulin G (IgG) isotype titers to .beta.-1,6-glucan in a subject; correlating the presence of a higher titer of IgG1 or IgG2 or IgG3, or a combination thereof, compared to IgG4 with responsiveness to a vaccine, adjuvant or composition comprising .beta.-1,6-glucan; and administering the vaccine, adjuvant or composition comprising .beta.-1,6-glucan to the subject based on the presence of a higher titer of IgG1 or IgG2 or IgG3, or a combination thereof, versus IgG4. 2. The method of claim 1, wherein the step of correlating comprises correlating the presence of a higher titer of IgG2 versus IgG4 with responsiveness to the vaccine, adjuvant or composition comprising .beta.-1,6-glucan; and wherein the step of administering comprises administering the vaccine, adjuvant or composition comprising .beta.-1,6-glucan to the subject based on the presence of a higher titer of IgG2 versus IgG4. 3. The method of claim 1, wherein the step of assessing is practiced on a biological sample isolated from the subject. 4. The method of claim 3, wherein the biological sample is serum or plasma. 5. The method of claim 1, wherein the relative immunoglobulin G (IgG) isotype titers are assessed using anti-IgG subclass-specific antibodies. 6. The method of claim 5, wherein the anti-IgG subclass-specific antibodies are labeled with a detectable marker. 7. The method of claim 6, wherein the detectable marker is selected from the group consisting of radioactive labels, fluorescent labels, chemiluminescent labels, chromophoric labels, ligands, fluorescein, radioisotopes, phosphatase, biotin, biotin-related compounds, avidin, avidin-related compounds, and peroxidase. 8. The method of claim 1, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an antibody. 9. The method of claim 8, wherein the antibody is a monoclonal antibody. 10. The method of claim 8, wherein the antibody is a human antibody. 11. The method of claim 8, wherein the antibody is a humanized antibody. 12. The method of claim 8, wherein the antibody is an antibody fragment. 13. The method of claim 12, wherein the antibody fragment is a Fab fragment, Fab' fragment, (Fab').sub.2 fragment, Fv fragment, a single chain antibody or a peptide coding for a single complementarity-determining region. 14. The method of claim 8, wherein the antibody is selected from the group consisting of Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab, Ibritumomab, Panitumumab, Rituximab, Tositumomab, Trastuzumab and Palivizumab. 15. The method of claim 8, wherein the antibody targets a neoplastic or preneoplastic cell. 16. The method of claim 15, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan promotes a host anticancer response. 17. The method of claim 15, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan promotes tumor cell lysis. 18. The method of claim 15, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan enhances a host antitumor response. 19. The method of claim 8, wherein the antibody targets an antigen expressed specifically on cancer cells. 20. The method of claim 19, wherein the vaccine, adjuvant or composition comprising .beta.-1,6-glucan enhances complement-mediated lysis of the cancer cells. 21. The method of claim 1 further comprising administering an agent to the subject which biases antibody production to yield relatively greater amounts of IgG1 or IgG2 or IgG3, or a combination thereof, versus IgG4; wherein the agent is administered prior to the vaccine, adjuvant or composition comprising .beta.-1,6-glucan. 22. The method of claim 21, wherein the agent is selected from the group consisting of cytokines, chemokines, complement components, immune system accessory and adhesion molecules and receptors of any of these. 23. The method of claim 22, wherein the agent is selected from the group consisting of interleukin 2, interleukin 12, interferon-gamma and combinations thereof. 24. The method of claim 21, wherein the agent is administered based on the presence of a lower titer of IgG1 or IgG2 or IgG3, or a combination thereof, versus IgG4. 25. The method of claim 21, wherein the agent is administered based on the presence of a lower titer of IgG2 versus IgG4. 26. The method of claim 2, wherein the composition is a pharmaceutical composition. 27. The method of claim 1, wherein the immunoglobulin G (IgG) isotype titers to .beta.-1,6-glucan result from exposure to environmental .beta.-1,6-glucan. 28. The method of claim 1, wherein the method comprises: assessing relative IgG2 and IgG4 isotype titers to .beta.-1,6-glucan in the subject; correlating the presence of a higher titer of IgG2 versus IgG4 with responsiveness to a vaccine, adjuvant or composition comprising .beta.-1,6-glucan; and administering the vaccine, adjuvant or composition comprising .beta.-1,6-glucan to the subject based on the presence of a higher titer IgG2 versus IgG4. 29. The method of claim 28, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an antibody. 30. A method comprising steps of: assessing a level of immunoglobulin G (IgG) 2 isotype titers to .beta.-1,6-glucan in a subject; correlating a level of IgG2 above a threshold with responsiveness to a vaccine, adjuvant or composition that comprises .beta.-1,6-glucan; and administering the vaccine, adjuvant or composition that comprises .beta.-1,6-glucan to the subject based on the presence of a level of IgG2 above the threshold. 31. The method of claim 30, wherein the glucan based vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an antibody. 32. The method of claim 31, wherein the composition is a pharmaceutical composition. 33. The method of claim 1, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an aptamer. 34. The method of claim 1, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to a peptide. 35. The method of claim 28, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an aptamer. 36. The method of claim 28, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to a peptide. 37. The method of claim 30, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to an aptamer. 38. The method of claim 30, wherein the vaccine, adjuvant or composition comprises .beta.-1,6-glucan linked to a peptide.

Details for Patent 8,617,823

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-04-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-04-29
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2028-04-29
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2028-04-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-04-29